Theravance Biopharma (TBPH) Stock Statistics & Valuation Metrics

Theravance Biopharma has a market cap or net worth of $902.48M. The enterprise value is $472.77M.

Theravance Biopharma has 50,672,432 shares outstanding. The number of shares has decreased by -2.65% in one year.

Theravance Biopharma’s return on equity (ROE) is -0.32 and return on invested capital (ROIC) is -17.84%.

The current PE Ratio of Theravance Biopharma is 31.3. Theravance Biopharma’s PEG ratio is -0.54.

In the last 12 months, Theravance Biopharma had revenue of 64.38M and earned -56.42M in profits. Earnings per share was -1.15.

In the last 12 months, operating cash flow was 243.70M and capital expenditures -224.00K, giving a free cash flow of 243.48M billion.

Theravance Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―

Theravance Biopharma upcoming earnings date is Mar 2, 2026, Before Open (Confirmed).

Theravance Biopharma as a current ratio of 5.02, with Debt / Equity ratio of 19.17%

In the past 12 months, Theravance Biopharma has paid 11.80M in taxes.

Theravance Biopharma EV to EBITDA ratio is -12.27, with an EV/FCF ratio of -39.75.

Theravance Biopharma has $329.68M in cash and marketable securities with $44.59M in debt, giving a net cash position of $285.08M billion.

Gross margin is 75.11%, with operating margin of -72.92%, and net profit margin of -87.63%.

The average price target for Theravance Biopharma is $28.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy